- Home
- SFWL vs ALLK Comparison
SFWL vs ALLK Comparison
Compare SFWL & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- ALLK
- Stock Information
- Founded
- SFWL 2001
- ALLK 2012
- Country
- SFWL China
- ALLK United States
- Employees
- SFWL N/A
- ALLK N/A
- Industry
- SFWL Trucking Freight/Courier Services
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- ALLK Health Care
- Exchange
- SFWL Nasdaq
- ALLK Nasdaq
- Market Cap
- SFWL 114.7M
- ALLK 101.0M
- IPO Year
- SFWL 2023
- ALLK 2018
- Fundamental
- Price
- SFWL $1.11
- ALLK $0.88
- Analyst Decision
- SFWL
- ALLK Hold
- Analyst Count
- SFWL 0
- ALLK 5
- Target Price
- SFWL N/A
- ALLK $1.67
- AVG Volume (30 Days)
- SFWL 80.2K
- ALLK 643.3K
- Earning Date
- SFWL 09-04-2024
- ALLK 11-06-2024
- Dividend Yield
- SFWL N/A
- ALLK N/A
- EPS Growth
- SFWL N/A
- ALLK N/A
- EPS
- SFWL 0.11
- ALLK N/A
- Revenue
- SFWL $446,281,000.00
- ALLK N/A
- Revenue This Year
- SFWL N/A
- ALLK N/A
- Revenue Next Year
- SFWL N/A
- ALLK N/A
- P/E Ratio
- SFWL $10.77
- ALLK N/A
- Revenue Growth
- SFWL 14.80
- ALLK N/A
- 52 Week Low
- SFWL $0.81
- ALLK $0.54
- 52 Week High
- SFWL $15.94
- ALLK $3.41
- Technical
- Relative Strength Index (RSI)
- SFWL 30.55
- ALLK 38.32
- Support Level
- SFWL $1.25
- ALLK $1.29
- Resistance Level
- SFWL $1.26
- ALLK $1.56
- Average True Range (ATR)
- SFWL 0.08
- ALLK 0.13
- MACD
- SFWL -0.02
- ALLK -0.07
- Stochastic Oscillator
- SFWL 3.57
- ALLK 10.53
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.